September 23, 2019
FDA: Class I recall of Allergan Natrelle Biocell textured breast implants
Editor's Note
The Food & Drug Administration (FDA) on September 12 designated the recall by Allergan of its Natrelle Biocell textured breast implants as Class I, the most serious.
The recall was initiated because of a six times higher rate of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a cancer of the immune system, which has been associated with these implants.
Distribution dates are September 14, 2014, to July 24, 2019.
Free Daily News
- Simulation-based robotic surgery training boosts team confidence, communication
- Perioperative leaders gather at 2025 OR Manager Conference
- CMS launches 6-year model to curb wasteful Medicare spending with AI-driven reviews
- Report: Hospitals can cut anesthesia costs, burnout through tech-driven partnerships
- Study: One in four US healthcare workers faces food insecurity
- Digital decision aid boosts shared decision-making in knee replacement consultations
- CMS narrows surveys to immediate jeopardy, harm during shutdown
- Ambient AI turns burnout relief into 'hard ROI' at Seattle Children’s
- Robotics redefine cardiac surgery with precision, smaller incisions, new frontiers in AI and telesurgery
- Private equity bets big on outpatient cardiology as CMS boosts reimbursements
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement